ACM
NUVB icon

ACT Capital Management’s Nuvation Bio NUVB Stock Holding History

ACT Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Sell
290,000
-320,500
-52% -$1.79M 0.98% 17
2025
Q4 		$5.47M Buy
+610,500
New +$3.78M 4.42% 9

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ACT Capital Management's NUVB Position: Q1 2026 in Review

ACT Capital Management reduced its Nuvation Bio (NUVB) stake by 52% in Q1 2026, selling an estimated $1.79M and leaving 290,000 shares worth $1.24M. The position accounts for 0.98% of the portfolio, ranked #17.

ACT Capital Management first reported a position in NUVB in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.47M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • ACT Capital Management held 290,000 shares of Nuvation Bio worth $1.24M as of Q1 2026.
  • ACT Capital Management sold 320,500 Nuvation Bio shares in Q1 2026, an estimated $1.79M.
  • Nuvation Bio made up 0.98% of ACT Capital Management's portfolio in Q1 2026, its #17 holding.
  • ACT Capital Management first reported a position in Nuvation Bio in Q4 2025 and has held it in 2 quarters since.
  • ACT Capital Management's Nuvation Bio position peaked at $5.47M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on ACT Capital Management's 13F filing for Q1 2026, filed 8 May 2026.